Bausch + Lomb

352 articles with Bausch + Lomb

• Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

  3/22/2023

  Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology.

• Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

  2/22/2023

  Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.

• New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

  2/7/2023

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

• Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

  2/1/2023

  Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE ® (Verteporfin for Injection).

• Bausch + Lomb Acquires AcuFocus, Inc.

  1/17/2023

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

• Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

  1/9/2023

  Bausch + Lomb Introduces Enhanced PreserVision ® AREDS 2 Formula Mini Soft Gels with OCUSorb ™.

• Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

  1/9/2023

  Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference.

• Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference.

• Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

  1/4/2023

  Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology.

• Bausch + Lomb Amends CEO Separation Agreement

  12/22/2022

  Bausch + Lomb Corporation announced that the Company and its CEO, Joseph C. Papa, have entered into an Amended and Restated Separation Agreement, pursuant to which Mr. Papa has agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board of Directors of the Company determines in its discretion or his successor is appointed, but no later than June 30, 2023.

• Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops

  12/13/2022

  Bausch + Lomb Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. 

• Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards

  12/12/2022

  Bausch + Lomb Corporation today announced its first-of-its-kind ONE by ONE and Biotrue Eye Care Recycling programs have been named a gold winner in the Most Environmentally Friendly Service of the Year category by the 2022 Best in Biz Awards.

• Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference

  11/7/2022

  Bausch + Lomb Corporation, today announced that Joseph C. Papa , chief executive officer, and Sam Eldessouky , executive vice president and chief financial officer are scheduled to participate at the 5th Annual Evercore ISI HealthCONx Conference on Nov. 30, 2022, at 9:40 a.m. ET.

• Bausch + Lomb Announces Third-Quarter 2022 Results

  11/2/2022

  Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2022 financial results.

• Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs

  10/24/2022

  Bausch + Lomb Corporation today announced the introduction of Project Watson health care products for dogs in the United States.

• Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2

  10/4/2022

  Bausch + Lomb Corporation will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022.

• Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

  9/27/2022

  Bausch + Lomb Corporation announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.

• Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

  9/26/2022

  Bausch + Lomb Corporation today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago from Sept. 30 to Oct. 3, 2022.

• Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings

  9/21/2022

  Bausch + Lomb Corporation today announced that data from the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2).

• First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+

  9/13/2022

  Bausch + Lomb Corporation released a report of survey results from the company's first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the 'blind spots' that may exist in the understanding and awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.